Figure 2. miR-588 as a novel regulator of CXCL5, CXCL9, and CXCL10 expression. (A) Immunohistochemistry of CXCL5, CXCL9, and CXCL10 expression in gastric tumors and corresponding nontumor adjacent gastric tissues. (B, C) Possible binding sites between miR-588 and CXCL5 and between miR-588 and CXCL9. (D) RT-PCR analysis of CXCL5, CXCL9, and CXCL10 mRNA relative to a control U6+. The relative level in MNK28 and SGC7901 cells was arbitrarily designated as 1. Each column represents the mean±SD from three biologic repeats. (E) Expression of CXCL5, CXCL9, and CXCL10 was examined using western blot analysis after overexpression of miR-588. (F) The cell viability inhibitory rate was determined using an MTT assay. MNK28 and SGC7901 cells were transfected with GV268-miR-588. (G) Crystal violet assay was performed to test cell growth after 48 hours of increased expression of miR-588, CXCL5, CXCL9, and CXCL10 in gastric cancer cells. (H) Metastatic capacity of MNK28 and SGC-7901 cells after 24 and 48 hours of increased expression of miR-588. (I) CXCL5, CXCL9, and CXCL10 focus on the immune response.